Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marion Merrell Dow’s Pentasa (mesalamine)

Executive Summary

Company will launch the product in the U.S. in early July following FDA approval May 10. Pentasa controlled-release capsules were approved for induction of remission and symptomatic treatment of mild-to-moderate active ulcerative colitis, a condition which MMD estimates affects more than 1 mil. Americans. Procter & Gamble markets Asacol mesalamine delayed-release tablets which are indicated for treating mildly to moderately active ulcerative colitis. Solvay markets Rowasa mesalamine enema and suppositories for mild-to-moderate distal ulcerative colitis, proctosigmoiditis or proctitis.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS022618

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel